Loading…
Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study
Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present...
Saved in:
Published in: | Aviation, space, and environmental medicine space, and environmental medicine, 2014-06, Vol.85 (6), p.638-644 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83 |
---|---|
cites | |
container_end_page | 644 |
container_issue | 6 |
container_start_page | 638 |
container_title | Aviation, space, and environmental medicine |
container_volume | 85 |
creator | Weerts, Aurélie P Vanspauwen, Robby Fransen, Erik Jorens, Philippe G Van de Heyning, Paul H Wuyts, Floris L |
description | Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths.
This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function.
Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees).
It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated. |
doi_str_mv | 10.3357/asem.3865.2014 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1677981727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1560116510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83</originalsourceid><addsrcrecordid>eNqNkTtPwzAURj2AaCmsjMgjAyl-xI-wVVV5SEUMhdmyHQcCThzsZOi_J1ULK0x3OfcM3wHgAqM5pUzc6OSaOZWczQnC-RGYIlSwjDNOJuA0pQ-EEM0JOgETkhe4oJJNgdp02jrYhL4OLUy1_WxdStCGoe1dbJxOQ3TpFmrYvevYaBt8eKut9rAMg_EuM75uy2vY-VFjQmZD28fgvSth6odyewaOK-2TOz_cGXi9W70sH7L18_3jcrHObC5In-WCcpqXFBuBkdCVE0bnwmKEiS5kTgmyhJaiEiUVxlSVZJVhgiKnBSdSSzoDV3tvF8PX4FKvmjpZ571uXRiSwlyIQmJBxN8o4whjzjD6B0rHdTmXZETne9TGkFJ0lepi3ei4VRipXR612Kye1C6P2uUZHy4P7sE0rvzFf9rQb_5tjU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535626682</pqid></control><display><type>article</type><title>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</title><source>IngentaConnect Journals</source><creator>Weerts, Aurélie P ; Vanspauwen, Robby ; Fransen, Erik ; Jorens, Philippe G ; Van de Heyning, Paul H ; Wuyts, Floris L</creator><creatorcontrib>Weerts, Aurélie P ; Vanspauwen, Robby ; Fransen, Erik ; Jorens, Philippe G ; Van de Heyning, Paul H ; Wuyts, Floris L</creatorcontrib><description>Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths.
This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function.
Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees).
It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.</description><identifier>ISSN: 0095-6562</identifier><identifier>DOI: 10.3357/asem.3865.2014</identifier><identifier>PMID: 24919385</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Antiemetics - therapeutic use ; Depression ; Dimenhydrinate ; Double-Blind Method ; Fatigue (materials) ; Healthy Volunteers ; Histamine H1 Antagonists - therapeutic use ; Humans ; Male ; Meclizine ; Middle Aged ; Motion sickness ; Nuclei ; Promethazine ; Semicircular canals ; Space life sciences ; Space Motion Sickness - drug therapy ; Young Adult</subject><ispartof>Aviation, space, and environmental medicine, 2014-06, Vol.85 (6), p.638-644</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24919385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weerts, Aurélie P</creatorcontrib><creatorcontrib>Vanspauwen, Robby</creatorcontrib><creatorcontrib>Fransen, Erik</creatorcontrib><creatorcontrib>Jorens, Philippe G</creatorcontrib><creatorcontrib>Van de Heyning, Paul H</creatorcontrib><creatorcontrib>Wuyts, Floris L</creatorcontrib><title>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</title><title>Aviation, space, and environmental medicine</title><addtitle>Aviat Space Environ Med</addtitle><description>Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths.
This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function.
Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees).
It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.</description><subject>Adult</subject><subject>Antiemetics - therapeutic use</subject><subject>Depression</subject><subject>Dimenhydrinate</subject><subject>Double-Blind Method</subject><subject>Fatigue (materials)</subject><subject>Healthy Volunteers</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Meclizine</subject><subject>Middle Aged</subject><subject>Motion sickness</subject><subject>Nuclei</subject><subject>Promethazine</subject><subject>Semicircular canals</subject><subject>Space life sciences</subject><subject>Space Motion Sickness - drug therapy</subject><subject>Young Adult</subject><issn>0095-6562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNkTtPwzAURj2AaCmsjMgjAyl-xI-wVVV5SEUMhdmyHQcCThzsZOi_J1ULK0x3OfcM3wHgAqM5pUzc6OSaOZWczQnC-RGYIlSwjDNOJuA0pQ-EEM0JOgETkhe4oJJNgdp02jrYhL4OLUy1_WxdStCGoe1dbJxOQ3TpFmrYvevYaBt8eKut9rAMg_EuM75uy2vY-VFjQmZD28fgvSth6odyewaOK-2TOz_cGXi9W70sH7L18_3jcrHObC5In-WCcpqXFBuBkdCVE0bnwmKEiS5kTgmyhJaiEiUVxlSVZJVhgiKnBSdSSzoDV3tvF8PX4FKvmjpZ571uXRiSwlyIQmJBxN8o4whjzjD6B0rHdTmXZETne9TGkFJ0lepi3ei4VRipXR612Kye1C6P2uUZHy4P7sE0rvzFf9rQb_5tjU0</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Weerts, Aurélie P</creator><creator>Vanspauwen, Robby</creator><creator>Fransen, Erik</creator><creator>Jorens, Philippe G</creator><creator>Van de Heyning, Paul H</creator><creator>Wuyts, Floris L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>L7M</scope></search><sort><creationdate>20140601</creationdate><title>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</title><author>Weerts, Aurélie P ; Vanspauwen, Robby ; Fransen, Erik ; Jorens, Philippe G ; Van de Heyning, Paul H ; Wuyts, Floris L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Antiemetics - therapeutic use</topic><topic>Depression</topic><topic>Dimenhydrinate</topic><topic>Double-Blind Method</topic><topic>Fatigue (materials)</topic><topic>Healthy Volunteers</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Meclizine</topic><topic>Middle Aged</topic><topic>Motion sickness</topic><topic>Nuclei</topic><topic>Promethazine</topic><topic>Semicircular canals</topic><topic>Space life sciences</topic><topic>Space Motion Sickness - drug therapy</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Weerts, Aurélie P</creatorcontrib><creatorcontrib>Vanspauwen, Robby</creatorcontrib><creatorcontrib>Fransen, Erik</creatorcontrib><creatorcontrib>Jorens, Philippe G</creatorcontrib><creatorcontrib>Van de Heyning, Paul H</creatorcontrib><creatorcontrib>Wuyts, Floris L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Aviation, space, and environmental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weerts, Aurélie P</au><au>Vanspauwen, Robby</au><au>Fransen, Erik</au><au>Jorens, Philippe G</au><au>Van de Heyning, Paul H</au><au>Wuyts, Floris L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</atitle><jtitle>Aviation, space, and environmental medicine</jtitle><addtitle>Aviat Space Environ Med</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>85</volume><issue>6</issue><spage>638</spage><epage>644</epage><pages>638-644</pages><issn>0095-6562</issn><abstract>Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths.
This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function.
Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees).
It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.</abstract><cop>United States</cop><pmid>24919385</pmid><doi>10.3357/asem.3865.2014</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0095-6562 |
ispartof | Aviation, space, and environmental medicine, 2014-06, Vol.85 (6), p.638-644 |
issn | 0095-6562 |
language | eng |
recordid | cdi_proquest_miscellaneous_1677981727 |
source | IngentaConnect Journals |
subjects | Adult Antiemetics - therapeutic use Depression Dimenhydrinate Double-Blind Method Fatigue (materials) Healthy Volunteers Histamine H1 Antagonists - therapeutic use Humans Male Meclizine Middle Aged Motion sickness Nuclei Promethazine Semicircular canals Space life sciences Space Motion Sickness - drug therapy Young Adult |
title | Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A35%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Space%20motion%20sickness%20countermeasures:%20a%20pharmacological%20double-blind,%20placebo-controlled%20study&rft.jtitle=Aviation,%20space,%20and%20environmental%20medicine&rft.au=Weerts,%20Aur%C3%A9lie%20P&rft.date=2014-06-01&rft.volume=85&rft.issue=6&rft.spage=638&rft.epage=644&rft.pages=638-644&rft.issn=0095-6562&rft_id=info:doi/10.3357/asem.3865.2014&rft_dat=%3Cproquest_cross%3E1560116510%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1535626682&rft_id=info:pmid/24919385&rfr_iscdi=true |